An aspect rarely commented on is that the DSM-5 leaders didn’t seem enthusiastic about the basic principles of the earlier revisions. In A Research Agenda for DSM-V, they said: Questions have been raised by many critics that the DSM’s descriptive approach may have outlived its usefulness and is in fact potentially misleading. Although there is […]
The Op-Ed: Antidepressants & Controversial Studies Pharmalot By Ed Silverman February 11th, 2013 Several years ago, the Black Box warnings that were added to antidepressants over suicidal thoughts and behaviors for youngsters caused a backlash, as some suggested the language had pushed physicians and parents to avoid usage when the medications could have done some […]
The Human Genome Project was declared complete in April 2003. An initial rough draft of the human genome was available in June 2000 and by February 2001 a working draft had been completed and published followed by the final sequencing mapping of the human genome on April 14, 2003… The Human Genome Project, Wikipedia Abbot […]
I started to list all the links to the bruhaha brewing over the AllTrials petition, but decided to summarize instead. There’s much posturing around the Alltrials petition, and all parties have behaved in an exemplary fashion [except for the other guys]. That’s it, the whole summary – meaning that the games have begun. Meanwhile, there […]
I don’t usually do this – republish someone else’s complete blog post. I try to pull out the parts I want to say something about or emphasize, then link the source in case you want to read the whole thing. But I could find nothing I wanted to take out of this post by Dr. […]
GSK statement of support for AllTrials campaign for clinical data transparency AllTrials Feb 6, 2013 We are pleased to sign up to the AllTrials campaign for clinical trial transparency and support its call for the registration of clinical trials and the disclosure of clinical trial results and clinical study reports. At GSK, we are committed […]
Awakening into consciousness in the post-WWII era, I was unaware how fortunate I was. There was a large radio in the living room for endless entertainment. And some nights, it was announced we were going to the movies – and we went. Some families planned such things in advance, but we just went. Unless it […]
The flooding of the literature with industry sponsored articles whose primary function was advertisement is well known to most of us. GlaxoSithKline’s Paxil studies authored by Scientific Therapeutic Information [Sally Laden] and Janssen’s series of Risperdal articles managed by Excerpta Medica come immediately to mind [Rothman Report]. In the complaint in a recent suit filed […]
Clinical Trials of various sorts are intended to be the final word in evaluating both the safety and the efficacy of medications. In psychiatry, they’re more complicated because the outcome parameters are from the subjective reporting of either observers or subjects converted to objective data by rating forms and checklists. Unfortunately, they’ve moved to center […]
A Tough Push For Clinical Trial Disclosure In Europe Pharmalot By Ed Silverman February 4th, 2013 As the debate over clinical trial transparency heats up, the lead legislator for the Environment, Public Health and Food Safety Committee in the European Parliament wants to toughen proposed legislation that is designed to bolster clinical trial practices and […]